Waters Stock Price, News & Analysis

Waters Corporation (NYSE:WAT) is set to host a live webcast of its Q1 2022 financial results conference call on May 3, 2022, at 8:00 a.m. Eastern Time. Interested parties can access the live presentation via Waters' investor relations website. A replay will be available until May 17, 2022, at midnight Eastern Time. Waters is renowned for its innovations in chromatography, mass spectrometry, and thermal analysis, with over 7,400 employees operating in 35 countries.

Waters Corporation (NYSE:WAT) has launched the Xevo TQ Absolute, advancing mass spectrometry technology. This new tandem quadrupole mass spectrometer is up to 15X more sensitive in quantifying negatively ionized compounds and 45% smaller than its competitors, using 50% less power and nitrogen. Designed for various analytical laboratories, it aims to enhance productivity and support sustainability goals. Shipments are expected to begin in May.

Waters Corporation (NYSE:WAT) has launched the Intact Mass application on the waters_connect platform, enabling faster and simplified biomolecule analysis. This software can confirm the mass and purity of biomolecules nearly twice as fast as existing options. The app is available as an upgrade for new and installed BioAccord LC-MS systems. Additionally, the introduction of Waters MaxPeak Premier columns enhances sensitivity by 2x to 3x compared to conventional steel columns, facilitating effective drug discovery processes.

Waters Corporation (NYSE:WAT) announced that its CEO, Udit Batra, will participate in a fireside chat at the Cowen Healthcare Conference on March 9, 2022, at 2:10 PM EST. Investors can access the live webcast on Waters’ investor relations website, with a replay available for 30 days. Waters Corporation has been a leader in chromatography, mass spectrometry, and thermal analysis for over 60 years, employing over 7,400 people globally and operating in 35 countries.

Waters Corporation (NYSE:WAT) will have its SVP & Chief Financial Officer, Amol Chaubal, participate in a virtual fireside chat at Citi’s 2022 Virtual Healthcare Conference on February 24 at 3:30 PM ET. Investors can access the live webcast through Waters’ investor relations website, with a replay available for 30 days. Waters Corporation is recognized for pioneering innovations in chromatography, mass spectrometry, and thermal analysis, serving various sectors for over 60 years, and operates in 35 countries with more than 7,400 employees.

Waters Corporation (NYSE:WAT) has acquired technology assets and intellectual property from Megadalton Solutions, enhancing its capabilities in Charge Detection Mass Spectrometry (CDMS). This acquisition allows Waters to overcome the limitations of traditional mass spectrometry, particularly in analyzing large proteins used in cell and gene therapies. The integration of CDMS technology is expected to expand Waters' product offerings and attract new customers in the biopharmaceutical sector, potentially boosting revenue from next-generation biologics.

Waters Corporation (NYSE: WAT) reported fourth quarter 2021 sales of $836 million, an increase of 6% as reported and 8% in constant currency from $787 million in Q4 2020. GAAP EPS rose to $3.52 from $3.49. Full-year sales reached $2,786 million, an 18% increase, with GAAP EPS at $11.17, up from $8.36. Despite ongoing pandemic challenges, strong growth was seen across biopharma and industrial sectors. The company expects 2022 sales growth of 5% to 7% and non-GAAP EPS of $11.75 to $12.00.

Waters Corporation (NYSE: WAT) announced that the U.S. FDA has expanded its use of Waters' Empower Chromatography Data Software and added NuGenesis Laboratory Management Software to support pharmaceutical testing. This transition to a common data management platform across five labs will enhance data retrieval and compliance with legislative mandates. Both software solutions will improve operational efficiencies for the FDA, allowing better management of analytical data vital for public health and safety.